Helsinn signs exclusive license deal with Juniper Biologics
Privately-held Swiss drugmaker Helsinn Group has signed an exclusive distribution and supply agreement with Singapore-based Juniper Biologics for Ledaga (chlormethine gel) in Australia, Asia and the Middle East as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adults.
This is the second deal between the companies this year, adding to similar arrangement to commercialize infigratinib (INN) in May.
Helsinn chief executive Giorgio Calderari commented: "I am pleased to announce this agreement with Juniper Biologics today which further widens the geographic distribution of Ledaga making this treatment option available to even more patients suffering from MF-CTCL. Juniper Biologics is an excellent partner for Helsinn and I’m looking forward to working with them to deliver on our mission to improve the lives of people with cancer all over the world."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze